CRISPR Therapeutics AG (CRSP) Price to FCF (2016 - 2026)

CRISPR Therapeutics AG has disclosed Price to FCF across 11 years of filings, most recently posting 62.65 for Q2 2026.

• In Q2 2026, Price to FCF fell 66.15% year-over-year to 62.65; the TTM figure through Jun 2026 stood at 14.2 (down 7.53% YoY), while the FY2025 annual figure was 14.54, up 37.68% from the prior year.
• Price to FCF came in at 62.65 for Q2 2026 at CRISPR Therapeutics AG, down from 41.91 in the prior quarter.
• In the past five years, Price to FCF ranged from a high of 621.43 in Q1 2023 to a low of 85.89 in Q3 2023.
• Average Price to FCF over 5 years is 5.92, with a median of 43.94 recorded in 2022.
• Year-over-year, Price to FCF tumbled 297.6% in 2022 and surged 2026.5% in 2023.
• Over 5 years, Price to FCF stood at 26.7 in 2022, then sank by 93.83% to 51.76 in 2023, then declined by 29.67% to 67.11 in 2024, then climbed by 19.49% to 54.03 in 2025, then declined by 15.95% to 62.65 in 2026.
• Per Business Quant data, the three most recent Price to FCF figures were 62.65 in Q2 2026, 41.91 in Q1 2026, and 54.03 in Q4 2025.